Hsu C.-S.JIA-HORNG KAO2021-09-042021-09-0420130815-9319https://www.scopus.com/inward/record.uri?eid=2-s2.0-84871654269&doi=10.1111%2fjgh.12024&partnerID=40&md5=f05361d79d7152c0cbb97a4661508046https://scholars.lib.ntu.edu.tw/handle/123456789/582022[SDGs]SDG33 hydroxy 3 methylglutaryl coenzyme A; antivirus agent; erythropoietin; fluindostatin; geranylgeranyl pyrophosphate; hydroxymethylglutaryl coenzyme A reductase inhibitor; interleukin 28B; peginterferon; proteinase inhibitor; ribavirin; triacylglycerol; very low density lipoprotein; add on therapy; anemia; blood transfusion; decompensated liver cirrhosis; disease course; editorial; enzyme activity; fatty liver; genotype; health care quality; hepatitis C; Hepatitis C virus; human; in vitro study; lipid metabolism; lipogenesis; liver failure; liver fibrosis; liver histology; low drug dose; patient care; prevalence; priority journal; protein secretion; randomized controlled trial (topic); recommended drug dose; relapse; treatment response; triacylglycerol blood level; upregulation; virus load; virus replicationEditorial10.1111/jgh.120242-s2.0-84871654269